Sima Porten, MD, MPH
Associate Professor
Urology
School of Medicine

Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer.

Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer.

Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology.

• Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
  Urologic oncology 2024 Lotan Y, Agarwal P, Black P, Dickstein R, Kamat AM, Lee B, Narayan VM, Porten S, Psutka SP, Smith AK, Svatek RS, Williams SB, Woldu S
• Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life.
  Bladder cancer (Amsterdam, Netherlands) 2023 Wang EY, Armas-Phan M, Meng MV, Loeb S, Kenfield SA, Porten SP
• Interruptions in bladder cancer care during the COVID-19 public health emergency.
  Urologic oncology 2023 Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, …
• Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
  BMC cancer 2023 Gore JL, Wolff EM, Comstock BA, Follmer KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, Lotan Y, Porten SP, Steinberg GD, Chang SS, Gilbert SM, Kessler LG, Smith AB, CISTO Collaborative
• Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
  European urology 2023 Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP
• Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
  European urology focus 2023 Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, Crispen P, Williams SB, Daneshmand S, Packiam VT, Porten S, Westerman ME, Wagner LI, Carducci M
• Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols.
  Urologic oncology 2023 Chappidi MR, Escobar D, Meng MV, Washington SL, Porten SP
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
  Urologic oncology 2023 Li KD, Chu CE, Patel M, Meng MV, Morgan TM, Porten SP
• Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
  Urologic oncology 2022 Alsyouf M, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light …
• Epidemiology, Screening, and Prevention of Bladder Cancer.
  European urology oncology 2022 Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y
• Sex-specific Augmentation of Treatment Responses in Bladder Cancer.
  European urology open science 2022 Chang K, Porten SP
• Which Biomarkers are Useful in the Management of Muscle-invasive Bladder Cancer in 2022?
  European urology focus 2022 Szymaniak J, Porten SP
• Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma.
  Molecular cancer research : MCR 2022 Wallace A, Porten SP, Lo AA, Oreper D, Lounsbury N, Havnar C, Pechuan-Jorge X, Zill OA, Meng MV
• Survey Results on Use of a Convex Pouching System in the Postoperative Period.
  Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society 2022 Stoia-Davis J, Colwell JC, Emodi K, Fellows J, Mahoney M, McDade B, Porten SP, Raskin ER, Norman HS, Kelly MT, Sims T
• Use of a Convex Pouching System in the Postoperative Period: A National Consensus.
  Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society 2022 Colwell JC, Stoia Davis J, Emodi K, Fellows J, Mahoney M, McDade B, Porten S, Raskin E, Sims T, Norman H, Kelly MT, Gray M
• Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer.
  Cancer immunology research 2022 Mujal AM, Combes AJ, Rao AA, Binnewies M, Samad B, Tsui J, Boissonnas A, Pollack JL, Argüello RJ, Meng MV, Porten SP, Ruhland MK, Barry KC, Chan V, Krummel MF
• Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care.
  Sleep medicine 2022 Robbins R, Cole R, Ejikeme C, Orstad SL, Porten S, Salter CA, Sanchez Nolasco T, Vieira D, Loeb S
• APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
  Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,…
• TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
  European urology oncology 2022 Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
• Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Prospective Multicenter Registry.
  Urology practice 2021 Stout TE, Regmi SK, Daneshmand S, Porten SP, Pohar KS, Konety BR
• Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.
  BJU international 2021 Ahmadi H, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light …
• Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
  The Journal of urology 2021 Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, Lotan Y, Porten SP, Kates M
• Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.
  European urology focus 2021 Tariq A, McCart Reed AE, Morton A, Porten S, Vela I, Williams ED, Yaxley JW, Black PC, Roberts MJ
• The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
  The Journal of urology 2021 Raman JD, Kavalieris L, Konety B, Porten S, Daneshmand S, Lotan Y, Loo R
• Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic.
  Urologic oncology 2021 Gore JL, Porten SP, Montgomery JS, Hamilton RJ, Meng MV, Sexton WJ, Psutka SP
• Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort.
  Urology 2021 Chappidi MR, Welty C, Choi W, Meng MV, Porten SP
• Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
• Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy.
  Urologic oncology 2021 Matulewicz RS, Ravvaz K, Weissert JA, Porten S, Steinberg GD, Blue Light Cystoscopy with Cysview Registry Group
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Research highlights of the 2020 society of urologic oncology young urologic oncologists' program.
  Urologic oncology 2021 Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SP
• Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
  European urology 2021 Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, …
• Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy.
  Urology 2020 Chu CE, Law L, Zuniga K, Lin TK, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, Carroll PR, Pruthi RS, Meng MV, Chen LL, Porten SP
• Women in Leadership in Urology: The Case for Increasing Diversity and Equity.
  Urology 2020 Chyu J, Peters CE, Nicholson TM, Dai JC, Taylor J, Garg T, Smith AB, Porten SP, Greene K, Browning N, Harris E, Sutherland SE, Psutka SP
• Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer.
  Cancer medicine 2020 Washington SL, Gregorich SE, Meng MV, Suskind AM, Porten SP
• Assessing Contemporary Trends in Female Speakership within Urologic Oncology.
  Urology 2020 Talwar R, Bernstein A, Jones A, Crook J, Apolo AB, Taylor JM, Burke LM, Plimack ER, Porten SP, Greene KL, Psutka SP, Smith AB
• Bladder tumor recurrence after urothelial carcinoma of the upper urinary tract.
  Translational andrology and urology 2020 Lonergan PE, Porten SP
• Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database.
  World journal of urology 2020 de la Calle CM, Washington SL, Lonergan PE, Meng MV, Porten SP
• Correction to: A comparison of stage-specific all-cause mortality between testicular sex cordstromal tumors and germ cell tumors: results from the National Cancer Database.
  BMC urology 2020 Zuniga KB, Washington SL, Porten SP, Meng MV
• Using provider-focused education toolkits can aid enhanced recovery programs to further reduce patient exposure to opioids.
  Perioperative medicine (London, England) 2020 Sarin A, Lancaster E, Chen LL, Porten S, Chen LM, Lager J, Wick E
• Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
  Cell 2020 Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L
• Reply by Authors.
  The Journal of urology 2020 de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA
• A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database.
  BMC urology 2020 Zuniga KB, Washington SL, Porten SP, Meng MV
• Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.
  Bladder cancer (Amsterdam, Netherlands) 2020 Zuniga KB, Graff RE, Feiger DB, Meng MV, Porten SP, Kenfield SA
• Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.
  European urology oncology 2020 de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, …
• TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.
  Molecular cancer research : MCR 2020 Mokkapati S, Porten SP, Narayan VM, Lim AH, Jayaratna IS, Roth B, Cheng T, Navai N, Wszolek M, Melquist J, Manyam G, Choi W, Broom B, Pretzsch S, Czerniak B, McConkey DJ, Dinney CPN
• A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
  The Journal of urology 2020 de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA
• An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.
  BMC urology 2020 Koya M, Osborne S, Chemaslé C, Porten S, Schuckman A, Kennedy-Smith A
• Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
  The Urologic clinics of North America 2020 Chu CE, Porten SP, Grossfeld GD, Meng MV
• Promotion Disparities in Academic Urology.
  Urology 2020 Breyer BN, Butler C, Fang R, Meeks W, Porten SP, North AC, Anger JT
• Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, …
• Gender differences in oncologic and functional outcomes in patients with bladder cancer undergoing radical cystectomy with urinary diversion.
  Current opinion in urology 2019 Sadighian M, Porten S
• Optimizing cystectomy outcomes.
  Cancer 2019 Porten SP, Master VA
• Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.
  European urology 2019 Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y
• Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019 Washington SL, Neuhaus J, Meng MV, Porten SP
• Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.
  European urology 2019 Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA
• The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice.
  Urology 2019 Washington SL, Porten SP, Quanstrom K, Jin C, Bridge M, Finlayson E, Walter LC, Suskind AM
• Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.
  Clinical genitourinary cancer 2019 Balakrishnan AS, Washington SL, Meng MV, Porten SP
• Epigenetic Alterations in Bladder Cancer.
  Current urology reports 2018 Porten SP
• Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape.
  European urology focus 2018 Psutka SP, Porten S
• Do Women Work Less Than Men in Urology: Data From the American Urological Association Census.
  Urology 2018 Porten SP, Gaither TW, Greene KL, Baradaran N, Anger JT, Breyer BN
• Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.
  Clinical epigenetics 2018 Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP
• Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.
  PloS one 2017 Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP
• The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.
  Cancer 2017 Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP
• Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis.
  Oncotarget 2017 Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C
• Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
  European urology focus 2017 Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB
• Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy.
  International journal of radiation oncology, biology, physics 2016 Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master…
• The Efficient and Effective Use of Exfoliative Urinary Markers.
  Urology practice 2016 Whitson JM, Porten SP, Hussein AA, Meng MV
• Intravesical chemotherapy in non-muscle-invasive bladder cancer.
  Indian journal of urology : IJU : journal of the Urological Society of India 2015 Porten SP, Leapman MS, Greene KL
• A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
  European urology 2015 McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO
• Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison.
  PloS one 2015 Sanford T, Porten S, Meng MV
• Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
  The Journal of urology 2015 Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR
• Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer.
  Current opinion in urology 2014 Porten SP, Willis D, Kamat AM
• Updated trends in imaging use in men diagnosed with prostate cancer.
  Prostate cancer and prostatic diseases 2014 Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR, Urologic Disease of America Project
• Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
  Cancer 2014 Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF
• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
  Cancer cell 2014 Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, …
• Xanthogranulomatous pyelonephritis presenting with a left flank mass.
  Case reports in medicine 2013 Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN
• Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.
  European urology 2013 Kamat AM, Porten S
• Should histologic variants alter definitive treatment of bladder cancer?
  Current opinion in urology 2013 Willis DL, Porten SP, Kamat AM
• Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
  The Journal of urology 2013 Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP
• Gunshot wounds to the lower urinary tract: a single-institution experience.
  The journal of trauma and acute care surgery 2013 Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN
• The role of active surveillance in the management of prostate cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M
• Active surveillance: does serial prostate biopsy increase histological inflammation?
  Prostate cancer and prostatic diseases 2013 Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR
• High-risk nonmuscle invasive bladder cancer: definition and epidemiology.
  Current opinion in urology 2012 Porten SP, Cooperberg MR
• Commentary on refractory ischemic priapism.
  Translational andrology and urology 2012 Garcia M, Porten S, Lue TF
• Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer.
  The Journal of urology 2011 Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR
• Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR
• Factors associated with downgrading in patients with high grade prostate cancer.
  Urologic oncology 2011 Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR
• The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
  The Journal of urology 2011 Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR
• The example of CaPSURE: lessons learned from a national disease registry.
  World journal of urology 2011 Porten SP, Cooperberg MR, Konety BR, Carroll PR
• Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.
  Nature reviews. Urology 2011 Whitson JM, Porten SP, Carroll PR
• The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply.
  Urology 2011 Myers JB, Porten SP, McAninch JW
• Outcomes of active surveillance for men with intermediate-risk prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR
• Disproportionate presentation of high risk prostate cancer in a safety net health system.
  The Journal of urology 2010 Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR
• Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers.
  The Journal of urology 2010 Eisner BH, Porten SP, Bechis SK, Stoller ML
• The role of race in determining 24-hour urine composition in white and Asian/Pacific Islander stone formers.
  The Journal of urology 2010 Eisner BH, Porten SP, Bechis SK, Stoller ML
• Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis.
  The Journal of urology 2009 Eisner BH, Porten SP, Bechis SK, Stoller ML
• Prevalence and severity of undiagnosed urinary incontinence in women.
  The American journal of medicine 2009 Wallner LP, Porten S, Meenan RT, O'Keefe Rosetti MC, Calhoun EA, Sarma AV, Clemens JQ
• The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease.
  BJU international 2009 Porten SP, Cooperberg MR, Carroll PR
• Diagnosis of female diverticula using magnetic resonance imaging.
  Advances in urology 2008 Porten S, Kielb S
• Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes.
  The Journal of urology 2007 Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE
• Math5 is required for both early retinal neuron differentiation and cell cycle progression.
  Developmental biology 2006 Le TT, Wroblewski E, Patel S, Riesenberg AN, Brown NL
• Math5 is required for retinal ganglion cell and optic nerve formation.
  Development (Cambridge, England) 2001 Brown NL, Patel S, Brzezinski J, Glaser T